DEVICE USER FEE PASSAGE THIS SESSION IN DOUBT
This article was originally published in The Gray Sheet
Executive SummaryDEVICE USER FEE PASSAGE THIS SESSION IN DOUBT as Congress nears the end of the legislative session. Factors working against passage of the Medical Device User Fee Act (HR 4864/S 2276), staffers say, include Congress' full agenda, members' desire to return to their districts and campaign for re-election, and a partisan debate on health care reform that is affecting negotiations on other legislation. The device user fee bill, which was introduced in the House and Senate on July 12 ("The Gray Sheet" July 18, p. 1), would impose fees on premarket applications for medical devices; the funds would be applied toward review functions within FDA's Center for Devices and Radiological Health. On the House side, the Energy and Commerce Committee approved the bill on Aug. 9 by a vote of 31 to 13 ("The Gray Sheet" Aug. 15, p. 1). The Senate has yet to take any action on the measure.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.